Compare · GDRX vs MEDS
GDRX vs MEDS
Side-by-side comparison of GoodRx Holdings Inc. (GDRX) and DataMeds AI Inc. (MEDS): market cap, price performance, sector, and recent activity on the wire.
Summary
- GDRX operates in Technology, while MEDS operates in Health Care - the two are in different parts of the market.
- GDRX is the larger of the two at $1.20B, about 386.3x MEDS ($3.1M).
- GDRX has been more active in the news (9 items in the past 4 weeks vs 6 for MEDS).
- GDRX has more recent analyst coverage (25 ratings vs 1 for MEDS).
- Company
- GoodRx Holdings Inc.
- DataMeds AI Inc.
- Price
- -
- -
- Market cap
- $1.20B
- $3.1M
- 1M return
- -
- -77.82%
- 1Y return
- -
- -98.02%
- Industry
- EDP Services
- Other Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 9
- 6
- Recent ratings
- 25
- 1
GoodRx Holdings Inc.
GoodRx Holdings, Inc., through its subsidiaries, provides information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including telehealth services. The company serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. GoodRx Holdings, Inc. was incorporated in 2015 and is based in Santa Monica, California.
DataMeds AI Inc.
DataMEDS AI, Inc. (NASDAQ:MEDS), formerly Wellgistics Health, Inc., is a healthcare company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its health information technology platforms to deliver a better experience for consumers and providers. Headquartered in Tampa, Fla., DataMEDS incorporates its EinsteinRx artificial intelligence platform and PharmacyChain blockchain-enabled smart contracts platform into the Health Lives Here mobile application from Tollo Health, LLC, and its pharmacy-related Corexa Health subsidiary provides pharmacy dispensing and pharmacy-related services, including distribution of products developed by Tollo Health. DataMEDS also owns Helomics Corporation, a Pittsburgh, PA -based commercial clinical molecular diagnostics laboratory focused on the ChemoFx Assay chemotherapy selection diagnostics test that aims to help oncologists make chemotherapy treatment decisions.
Latest GDRX
- Chief Accounting Officer Chan Thomas (Tc) converted options into 8,864 shares and covered exercise/tax liability with 4,511 shares, increasing direct ownership by 25% to 21,776 units (SEC Form 4)
- Officer Fengler Justin converted options into 54,233 shares and covered exercise/tax liability with 23,783 shares, increasing direct ownership by 43% to 101,202 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by GoodRx Holdings Inc.
- GoodRx Brings Prescription Pricing Intelligence to Google Cloud’s Gemini for Healthcare
- Director Bruehlman Ronald E converted options into 21,692 shares, increasing direct ownership by 10% to 229,044 units (SEC Form 4)
- Director Bezdek Trevor converted options into 34,975 shares, increasing direct ownership by 10% to 378,785 units (SEC Form 4)
- GoodRx Holdings Inc. filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
- GoodRx Launches Employer Direct Weight Loss Offering
- SEC Form 4 filed by GoodRx Holdings Inc.
- SEC Form 4 filed by GoodRx Holdings Inc.
Latest MEDS
- UPDATING ORIGINAL RELEASE DataMEDS AI Releases CEO Letter
- DataMEDS AI Releases CEO Letter
- DataMEDS AI Reports 50% Sequential Revenue Growth in Third Quarter 2026 From Second Quarter 2026, Delivers Net Profit Per Share of $2.72 and Provides Business Update
- DataMEDS AI Signs MOU to Deploy Health Lives Here GLP-1 Patient Management Program with Florida-Based HMO
- DataMEDS AI Announces Termination of Second Amended and Restated Letter of Intent
- DataMEDS AI Enters Into Agreement for Commercial Supply of Six Peptides Recommended by FDA Advisory Committee
- DataMEDS AI Establishes "Health Lives Here" Community Respiratory Program for Corexa Health Pharmacy Network
- Datavault AI Signs Non-Binding Letter of Intent to Acquire a 19.9% Equity Stake in DataMEDS AI in Consideration of an Expanded Technology License
- DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies
- DataMeds Regains Compliance With NASDAQ Listing Standards